Citadel Advisors’s Globus Medical GMED Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.98M | Buy |
46,200
+5,200
| +13% | +$467K | ﹤0.01% | 4721 |
|
|
2025
Q4 | $3.58M | Sell |
41,000
-25,500
| -38% | -$1.94M | ﹤0.01% | 4841 |
|
|
2025
Q3 | $3.81M | Sell |
66,500
-4,600
| -6% | -$265K | ﹤0.01% | 4863 |
|
|
2025
Q2 | $4.2M | Sell |
71,100
-20,500
| -22% | -$1.32M | ﹤0.01% | 4414 |
|
|
2025
Q1 | $6.71M | Buy |
91,600
+70,800
| +340% | +$5.85M | ﹤0.01% | 3434 |
|
|
2024
Q4 | $1.72M | Buy |
20,800
+1,300
| +7% | +$103K | ﹤0.01% | 5945 |
|
|
2024
Q3 | $1.4M | Sell |
19,500
-50,500
| -72% | -$3.56M | ﹤0.01% | 6195 |
|
|
2024
Q2 | $4.79M | Sell |
70,000
-29,500
| -30% | -$1.76M | ﹤0.01% | 3810 |
|
|
2024
Q1 | $5.34M | Buy |
99,500
+16,100
| +19% | +$866K | ﹤0.01% | 3860 |
|
|
2023
Q4 | $4.44M | Buy |
83,400
+71,400
| +595% | +$3.48M | ﹤0.01% | 3977 |
|
|
2023
Q3 | $596K | Sell |
12,000
-69,400
| -85% | -$3.88M | ﹤0.01% | 7679 |
|
|
2023
Q2 | $4.85M | Sell |
81,400
-20,000
| -20% | -$1.14M | ﹤0.01% | 3700 |
|
|
2023
Q1 | $5.74M | Buy |
101,400
+34,000
| +50% | +$2.18M | ﹤0.01% | 3575 |
|
|
2022
Q4 | $5.01M | Buy |
67,400
+33,200
| +97% | +$2.26M | ﹤0.01% | 3863 |
|
|
2022
Q3 | $2.04M | Buy |
34,200
+5,500
| +19% | +$331K | ﹤0.01% | 5546 |
|
|
2022
Q2 | $1.61M | Sell |
28,700
-9,100
| -24% | -$598K | ﹤0.01% | 6001 |
|
|
2022
Q1 | $2.79M | Sell |
37,800
-6,300
| -14% | -$438K | ﹤0.01% | 5366 |
|
|
2021
Q4 | $3.18M | Buy |
44,100
+8,200
| +23% | +$595K | ﹤0.01% | 5218 |
|
|
2021
Q3 | $2.75M | Buy |
35,900
+14,700
| +69% | +$1.18M | ﹤0.01% | 5569 |
|
|
2021
Q2 | $1.64M | Sell |
21,200
-33,900
| -62% | -$2.41M | ﹤0.01% | 7098 |
|
|
2021
Q1 | $3.4M | Buy |
55,100
+32,300
| +142% | +$2.05M | ﹤0.01% | 5145 |
|
|
2020
Q4 | $1.49M | Sell |
22,800
-47,000
| -67% | -$2.7M | ﹤0.01% | 5979 |
|
|
2020
Q3 | $3.46M | Buy |
69,800
+8,800
| +14% | +$454K | ﹤0.01% | 3730 |
|
|
2020
Q2 | $2.91M | Sell |
61,000
-39,800
| -39% | -$1.92M | ﹤0.01% | 3914 |
|
|
2020
Q1 | $4.29M | Buy |
100,800
+75,800
| +303% | +$3.74M | ﹤0.01% | 2933 |
|
|
2019
Q4 | $1.47M | Buy |
25,000
+18,400
| +279% | +$999K | ﹤0.01% | 4905 |
|
|
2019
Q3 | $337K | Buy |
+6,600
| New | +$314K | ﹤0.01% | 7389 |
|
|
2019
Q2 | – | Sell |
-4,900
| Closed | -$242K | – | 9418 |
|
|
2019
Q1 | $242K | Sell |
4,900
-10,500
| -68% | -$475K | ﹤0.01% | 7921 |
|
|
2018
Q4 | $667K | Sell |
15,400
-14,300
| -48% | -$713K | ﹤0.01% | 5951 |
|
|
2018
Q3 | $1.69M | Buy |
29,700
+10,400
| +54% | +$547K | ﹤0.01% | 4679 |
|
|
2018
Q2 | $974K | Buy |
19,300
+12,500
| +184% | +$652K | ﹤0.01% | 5263 |
|
|
2018
Q1 | $339K | Sell |
6,800
-200
| -3% | -$9.4K | ﹤0.01% | 6539 |
|
|
2017
Q4 | $288K | Sell |
7,000
-1,300
| -16% | -$45.5K | ﹤0.01% | 6525 |
|
|
2017
Q3 | $247K | Buy |
+8,300
| New | +$253K | ﹤0.01% | 6364 |
|
|
2016
Q1 | – | Sell |
-3,300
| Closed | -$92K | – | 7208 |
|
|
2015
Q4 | $92K | Sell |
3,300
-3,000
| -48% | -$75.3K | ﹤0.01% | 6781 |
|
|
2015
Q3 | $130K | Buy |
6,300
+4,600
| +271% | +$117K | ﹤0.01% | 6682 |
|
|
2015
Q2 | $44K | Sell |
1,700
-1,500
| -47% | -$38K | ﹤0.01% | 7734 |
|
|
2015
Q1 | $81K | Sell |
3,200
-5,200
| -62% | -$127K | ﹤0.01% | 7011 |
|
|
2014
Q4 | $200K | Buy |
8,400
+2,300
| +38% | +$50.9K | ﹤0.01% | 5984 |
|
|
2014
Q3 | $120K | Sell |
6,100
-3,400
| -36% | -$70K | ﹤0.01% | 6237 |
|
|
2014
Q2 | $227K | Buy |
9,500
+7,500
| +375% | +$181K | ﹤0.01% | 5427 |
|
|
2014
Q1 | $53K | Buy |
+2,000
| New | +$47.5K | ﹤0.01% | 6738 |
|
Other funds holding GMED
VCM
VPM
SC
Citadel Advisors's GMED Position: Q1 2026 in Review
Citadel Advisors reduced its Globus Medical (GMED) stake by 23% in Q1 2026, selling an estimated $51.5M and leaving 1,966,114 shares worth $169M. The position accounts for 0.03% of the portfolio, ranked #521.
Citadel Advisors first reported a position in GMED in Q3 2013 and has held it in 49 quarters since. The position peaked at $222M in Q4 2025. 603 funds tracked by Wall St. Rank hold GMED as of Q1 2026.
- Citadel Advisors held 1,966,114 shares of Globus Medical worth $169M as of Q1 2026.
- Citadel Advisors sold 573,282 Globus Medical shares in Q1 2026, an estimated $51.5M.
- Globus Medical made up 0.03% of Citadel Advisors's portfolio in Q1 2026, its #521 holding.
- Citadel Advisors first reported a position in Globus Medical in Q3 2013 and has held it in 49 quarters since.
- Citadel Advisors's Globus Medical position peaked at $222M in Q4 2025.
- 603 funds tracked by Wall St. Rank held Globus Medical as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.